How many drugs treat Myasthenia gravis?

Drug Landscape tracks 9 marketed treatments for Myasthenia gravis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myasthenia-gravis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myasthenia gravis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myasthenia gravis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myasthenia gravis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vyvgart	EFGARTIGIMOD ALFA	Argenx Bv	Endoglycosidase [EPC]	IgG receptor FcRn large subunit p51	2021-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	Complement Inhibitor [EPC]	Complement C5	2018-01-01
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Imuran	AZATHIOPRINE	Legacy Pharma	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01
Mytelase	AMBENONIUM	Sanofi	Cholinesterase Inhibitor	Acetylcholinesterase	1956-01-01
Ultomiris	Ultomiris	Alexion Pharmaceuticals, Inc.		Complement C5
Ubretid	DISTIGMINE	Torii Pharmaceuticals	distigmine	Acetylcholinesterase
ULTOMIRIS	RAVULIZUMAB-CWVZ	ALEXION PHARM		Complement C5
Efgartigimod	Efgartigimod	M. Peter Marinkovich	Endoglycosidase [EPC]	FcRn

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

ALEXION PHARM · 1 drug in Myasthenia gravis
Alexion Pharmaceuticals, Inc. · 1 drug in Myasthenia gravis
Argenx Bv · 1 drug in Myasthenia gravis
AstraZeneca · 1 drug in Myasthenia gravis
Fresenius Kabi · 1 drug in Myasthenia gravis
Legacy Pharma · 1 drug in Myasthenia gravis
M. Peter Marinkovich · 1 drug in Myasthenia gravis
Sanofi · 1 drug in Myasthenia gravis
Torii Pharmaceuticals · 1 drug in Myasthenia gravis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myasthenia gravis:

Cite this brief

Drug Landscape (2026). Myasthenia gravis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myasthenia-gravis. Accessed 2026-06-10.

Myasthenia gravis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing